Zain Guduru, MD
Neurology · Lexington, KYNPI 1215291398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $607 and has fallen 88.3% since, to $71 in 2023. That places this record below the midpoint for neurology clinicians in KY, where the typical reported total is $1,714.
Across 39 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$253
- Acadia Pharmaceuticals Inc$193
- UCB, Inc.$175
- Teva Pharmaceuticals USA, Inc.$133
- Sunovion Pharmaceuticals Inc.$119
- CSL Behring$93
- plus $105 from 6 others
Across 9 payments — averaging $4166.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Integrative Research Laboratories Sweden AB$32K
- AbbVie$6K
What the payments were for
- Food & beverage$1,071100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $253 |
| Acadia Pharmaceuticals Inc | 3 | $193 |
| UCB, Inc. | 11 | $175 |
| Teva Pharmaceuticals USA, Inc. | 8 | $133 |
| Sunovion Pharmaceuticals Inc. | 2 | $119 |
| CSL Behring | 4 | $93 |
| Neurocrine Biosciences, Inc. | 2 | $28 |
| AbbVie | 1 | $21 |
| Novartis | 1 | $17 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Adamas Pharmaceuticals, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL DBS$147
- NUPLAZID$112
- APTIOM$105
How this compares
$1,071 in reported general payments places this provider in the 40th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 36 | $286,620 |
| IngrezzaValbenazine Tosylate | 26 | $178,909 |
| NuplazidPimavanserin Tartrate | 14 | $62,323 |
| Tetrabenazine | 18 | $49,141 |
| RytaryCarbidopa/Levodopa | 16 | $43,489 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 171 | $8,693 |
| DayvigoLemborexant | 11 | $6,820 |
| MyrbetriqMirabegron | 12 | $5,884 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 16 | $3,392 |
| Dalfampridine ErDalfampridine | 12 | $2,767 |
| Rivastigmine | 26 | $2,101 |
| Levetiracetam | 31 | $1,478 |
| Primidone | 53 | $962 |
| Fludrocortisone Acetate | 13 | $555 |
| Propranolol Hcl ErPropranolol Hcl | 11 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $133 | $286,62036 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $28 | $178,90926 claims |
| Acadia Pharmaceuticals IncNuplazid | $193 | $62,32314 claims |
| Amneal Pharmaceuticals LLCRytary | $11 | $43,48916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 210 neurology providers in Kentucky.
Other neurology in Lexington
- James WinkleyLexington$807K
- Nicole EvermanLexington$355K
- Toufic FakhouryLexington$278K
- Fred OdagoLexington$28K
- Zabeen MahuwalaLexington$28K
- Jagannadha AvasaralaLexington$15K
- Joshua ChalkleyLexington$15K
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Naveed AhmedPikeville$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.